Want to see HK:2171 full AI Analyst Report?
Top Page
CARsgen Therapeutics Holdings Ltd.
(2171)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$14.00
▼(-5.98% Downside)
Action:Reiterated
Date:06/26/26
The score is weighed down primarily by persistent losses and continued negative operating cash flow despite improving revenue traction and positive gross profit. Technicals add further pressure as the stock remains in a clear downtrend (below major moving averages with negative MACD). Valuation provides limited support because the company is loss-making and no dividend yield is available.
Positive Factors
Revenue & Gross Profit Improvement
Material revenue growth with gross profit turning positive indicates improving unit economics and early commercial traction. This durable improvement supports future margin expansion as fixed R&D and SG&A are leveraged, reducing reliance on financing if growth persists over coming quarters.
Negative Factors
Deep Negative Operating Cash Flow
Persistent, large negative operating cash flow demonstrates the business is not self-funding operations. Continued cash burn necessitates external financing or dilution, constraining strategic choices and raising execution risk if capital markets tighten over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Gross Profit Improvement
Material revenue growth with gross profit turning positive indicates improving unit economics and early commercial traction. This durable improvement supports future margin expansion as fixed R&D and SG&A are leveraged, reducing reliance on financing if growth persists over coming quarters.
Read all positive factors
CARsgen Therapeutics Holdings Ltd. (2171) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.90B
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue Growth219.26%
EPS Growth87.63%
CountryHK
Employees355
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding601,455,000
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)9.40
Price to Sales (P/S)58.60
P/FCF Ratio-30.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.70Price Target Upside72.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)HK$433.36M
CARsgen Therapeutics Holdings Ltd. Business Overview & Revenue Model
Company Description
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts...
How the Company Makes Money
null...
CARsgen Therapeutics Holdings Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 125.66M | 39.42M | 0.00 | 0.00 | 25.81M |
| Gross Profit | 79.95M | 14.75M | -96.57M | -94.81M | 25.81M |
| EBITDA | -203.91M | -686.61M | -717.64M | -748.73M | -4.67B |
| Net Income | -97.86M | -798.13M | -747.79M | -892.25M | -4.74B |
Balance Sheet | |||||
| Total Assets | 1.29B | 1.67B | 2.26B | 2.76B | 3.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.12B | 1.48B | 1.85B | 2.27B | 3.01B |
| Total Debt | 61.20M | 166.42M | 85.22M | 119.44M | 338.05M |
| Total Liabilities | 513.02M | 616.33M | 455.51M | 289.64M | 508.98M |
| Stockholders Equity | 783.65M | 1.06B | 1.80B | 2.47B | 3.00B |
Cash Flow | |||||
| Free Cash Flow | -243.03M | -429.26M | -464.48M | -781.66M | -690.77M |
| Operating Cash Flow | -228.44M | -409.69M | -454.94M | -643.05M | -512.32M |
| Investing Cash Flow | -2.88M | 12.52M | 39.25M | 2.39B | -2.47B |
| Financing Cash Flow | -111.72M | 18.46M | -22.14M | -236.51M | 2.67B |
CARsgen Therapeutics Holdings Ltd. Technical Analysis
Negative
14.89
Price Trends
17.76
Negative
17.35
Negative
17.19
Negative
Market Momentum
-0.66
Negative
43.11
Neutral
64.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2171, the sentiment is Negative. The current price of 14.89 is below the 20-day moving average (MA) of 15.09, below the 50-day MA of 17.76, and below the 200-day MA of 17.19, indicating a bearish trend. The MACD of -0.66 indicates Negative momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 64.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2171.
CARsgen Therapeutics Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$17.43B | -11.91 | -24.29% | ― | 8.50% | 35.24% | |
46 Neutral | HK$7.12B | -54.27 | -6.26% | ― | -11.65% | -169.40% | |
44 Neutral | HK$8.90B | -71.26 | -11.21% | ― | 219.26% | 87.63% | |
42 Neutral | HK$36.46B | -55.38 | -10.78% | ― | 34.19% | 47.97% | |
42 Neutral | HK$741.78M | -1.15 | -75.15% | ― | 79.76% | 6.45% | |
41 Neutral | HK$8.16B | -21.58 | -64.78% | ― | -33.37% | -344.90% |
* Healthcare Sector Average
HK:2171
CARsgen Therapeutics Holdings Ltd.
14.56
-7.04
-32.59%
HK:9688
Zai Lab Ltd
15.34
-11.86
-43.60%
HK:9966
Alphamab Oncology
7.28
0.73
11.15%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
18.58
-4.97
-21.10%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
1.75
-0.99
-36.13%
HK:2616
CStone Pharmaceuticals
5.14
-0.20
-3.75%
CARsgen Therapeutics Holdings Ltd. Corporate Events
CARsgen Launches Discretionary Share Buyback Worth Up to 5% of Capital
Jun 26, 2026
CARsgen Therapeutics Holdings Ltd. has initiated a share repurchase plan under a previously approved mandate, allowing the company to buy back up to 30,124,699 shares, or about 5% of its issued share capital as of May 31, 2026. The repurchases, wh...
CARsgen Wins First-Ever Global Approval for Solid-Tumor CAR T Therapy in China
Jun 22, 2026
CARsgen has secured Chinese regulatory approval for satricabtagene autoleucel, an autologous CAR T-cell therapy targeting Claudin18.2, for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcino...
CARsgen Advances Allogeneic CAR T Programs After Positive Early Data at EHA 2026
Jun 15, 2026
CARsgen Therapeutics announced updated research results for its allogeneic CAR T-cell candidates CT0596 and CT1190B, which were presented as first-in-human poster studies at the 2026 European Hematology Association Congress. The data showed prelim...
CARsgen Showcases New Satri-cel Data as It Expands Claudin18.2 CAR T Strategy
Jun 1, 2026
CARsgen Therapeutics has reported updated long-term research results for its autologous CAR T-cell candidate satricabtagene autoleucel, or satri-cel, targeting Claudin18.2-positive tumors, presented as a poster at the 2026 ASCO Annual Meeting. The...
CARsgen completes HK$19.84-per-share placing and top-up subscription
May 26, 2026
CARsgen Therapeutics Holdings Ltd. has completed a placing of 23.7 million existing shares at HK$19.84 per share to at least six independent investors through joint placing agents, under a general mandate. All placees and their ultimate beneficial...
CARsgen Adds Directors’ Responsibility Statement to Share Placement Disclosure
May 22, 2026
CARsgen Therapeutics Holdings Ltd., a Hong Kong-listed biotechnology company specializing in oncology-focused cell therapies such as CAR-T treatments, operates in the global biopharmaceutical market with an emphasis on advanced cancer immunotherap...
CARsgen Shareholders Back All AGM Resolutions, Strengthening Board Mandates and Governance
May 22, 2026
Shareholders of CARsgen Therapeutics Holdings Ltd. approved all resolutions at the annual general meeting held on 22 May 2026, including the adoption of the 2025 audited financial statements, re-election of three executive directors and authorizat...
CARsgen Raises Capital via Discounted Share Placing to Accelerate Global CAR T R&D
May 15, 2026
CARsgen Therapeutics has launched a top-up placing and subscription of up to 23.7 million shares, representing about 4.15% of its existing issued share capital, at HK$19.84 per share, a discount to recent market prices. The structure involves an e...
CARsgen Advances Allogeneic CAR T Programs as EHA Accepts New Data for 2026
Apr 27, 2026
CARsgen Therapeutics said investigator-initiated trial data for its allogeneic CAR T-cell candidates CT0596 and CT1190B have been accepted for poster presentation at the 2026 European Hematology Association congress, underscoring progress in its o...
CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Apr 10, 2026
CARsgen Therapeutics Holdings Limited has convened its annual general meeting for 22 May 2026 in Shanghai, where shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025 and the accompanying directors...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.